{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:15:28Z","timestamp":1791213328909,"version":"4.1.0"},"reference-count":78,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2014,12,29]],"date-time":"2014-12-29T00:00:00Z","timestamp":1419811200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0116153","type":"journal-article","created":{"date-parts":[[2014,12,29]],"date-time":"2014-12-29T18:58:26Z","timestamp":1419879506000},"page":"e116153","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":30,"title":["MABGEL 1: First Phase 1 Trial of the Anti-HIV-1 Monoclonal Antibodies 2F5, 4E10 and 2G12 as a Vaginal Microbicide"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"isrctn64808733","registry":"10.18810\/isrctn"}],"author":[{"given":"Georgina C.","family":"Morris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C.","family":"Wiggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Woodhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Martin","family":"Bland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol R.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Jespers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitta A.","family":"Vcelar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Lacey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,12,29]]},"reference":[{"key":"ref1","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS)<bold>.<\/bold> (2012) UNAIDS report on the global AIDS epidemic 2012. Geneva: UNAIDS. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.unaids.org\/en\/media\/unaids\/contentassets\/documents\/epidemiology\/2012\/gr2012\/20121120_UNAIDS_Global_Report_2012_with_annexes_en.pdf\" xlink:type=\"simple\">http:\/\/www.unaids.org\/en\/media\/unaids\/contentassets\/documents\/epidemiology\/2012\/gr2012\/20121120_UNAIDS_Global_Report_2012_with_annexes_en.pdf<\/ext-link>. Accessed 2013 May 30."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"MS Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"JM Baeten","year":"2012","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"L Van Damme","year":"2012","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"MC Thigpen","year":"2012","journal-title":"N Engl J Med"},{"key":"ref6","unstructured":"Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, <etal>et al<\/etal>.<bold>.<\/bold> (2013) Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir\/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003). Late breaker Abstract #26LB. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, March 3\u20136, 2013."},{"key":"ref7","first-page":"524","article-title":"Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science 329: 1168\u20131174","volume":"333","author":"Q Abdool Karim","year":"2010","journal-title":"Erratum (2011) in Science"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"13232","DOI":"10.1128\/JVI.78.23.13232-13252.2004","article-title":"Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies","volume":"78","author":"JM Binley","year":"2004","journal-title":"J Virol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"LM Walker","year":"2009","journal-title":"Science"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"LM Walker","year":"2011","journal-title":"Nature"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1089\/08892220152741450","article-title":"A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1","volume":"17","author":"G Stiegler","year":"2001","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"10690","DOI":"10.1128\/JVI.01110-10","article-title":"Antibody 2G12 recognizes di-mannose equivalently in domain- and non-domain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged","volume":"84","author":"KJ Doores","year":"2010","journal-title":"J Virol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/72309","article-title":"Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian human immunodeficiency virus infection","volume":"6","author":"TW Baba","year":"2000","journal-title":"Nat Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1128\/JVI.73.5.4009-4018.1999","article-title":"Protection of macaques against pathogenic simian\/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies","volume":"73","author":"JR Mascola","year":"1999","journal-title":"J Virol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/72318","article-title":"Protection of macaques against vaginal transmission of a pathogenic HIV-1\/SIV chimeric virus by passive infusion of neutralizing antibodies","volume":"6","author":"JR Mascola","year":"2000","journal-title":"Nat Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1128\/JVI.01272-09","article-title":"Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIV<sub>Ba-L<\/sub>","volume":"84","author":"AJ Hessell","year":"2010","journal-title":"J Virol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00002030-200201250-00012","article-title":"A phase I trial with two human monoclonal antibodies (hmAb 2F5, 2G12) against HIV-1","volume":"16","author":"C Armbruster","year":"2002","journal-title":"AIDS"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/jac\/dkh428","article-title":"Passive immunization with the anti-HIV-1 human monoclonal antibody (hmAb) 4E10 and the hmAb combination 4E10\/2F5\/2G12","volume":"54","author":"C Armbruster","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nm1244","article-title":"Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies","volume":"11","author":"A Trkola","year":"2005","journal-title":"Nat Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"11016","DOI":"10.1128\/JVI.01340-07","article-title":"Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early Infection","volume":"81","author":"S Mehandru","year":"2007","journal-title":"J Virol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1097\/QAD.0b013e328285da15","article-title":"Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data","volume":"21","author":"B Vcelar","year":"2007","journal-title":"AIDS"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"6548","DOI":"10.1128\/JVI.02749-06","article-title":"Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors","volume":"81","author":"AK Dhillon","year":"2007","journal-title":"J Virol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/JVI.02631-08","article-title":"In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth","volume":"83","author":"X Shen","year":"2009","journal-title":"J Virol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e1001028.","DOI":"10.1371\/journal.ppat.1001028","article-title":"A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals","volume":"6","author":"LM Walker","year":"2010","journal-title":"PLoS Pathog"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1126\/science.1225416","article-title":"Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses","volume":"337","author":"DR Burton","year":"2012","journal-title":"Science"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3233\/HAB-2005-143-402","article-title":"Antibody polyspecificity and neutralization of HIV-1: a hypothesis","volume":"14","author":"BF Haynes","year":"2005","journal-title":"Hum Antibodies"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1126\/science.1111781","article-title":"Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies","volume":"308","author":"BF Haynes","year":"2005","journal-title":"Science"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1097\/QAD.0b013e3282a4a632","article-title":"Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity","volume":"21","author":"EM Scherer","year":"2007","journal-title":"AIDS"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0090-1229(95)90138-8","article-title":"Anticardiolipin antibodies are associated with antiendothelial cell antibodies but not with antibeta 2 glycoprotein I antibodies in HIV infection","volume":"77","author":"L Weiss","year":"1995","journal-title":"Clin Immunol Immunopathol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1055\/s-0038-1656067","article-title":"Autoantibodies to phospholipids and to the coagulation proteins in AIDS","volume":"77","author":"N Abuaf","year":"1997","journal-title":"Thromb Haemost"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1006\/jaut.1999.0324","article-title":"Antiphospholipid antibodies in HIV infection and SLE with or without antiphospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI","volume":"13","author":"C Petrovas","year":"1999","journal-title":"J Autoimmun"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/ard.62.11.1106","article-title":"Anticardiolipin, antibeta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease","volume":"62","author":"S Loizou","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2180-12-83","article-title":"Quantification of bacterial species of the vaginal microbiome in different groups of women, using nucleic acid amplification tests","volume":"12","author":"V Jespers","year":"2012","journal-title":"BMC Microbiol"},{"key":"ref34","unstructured":"Jespers V, Morris G, Nel A, Lacey C, Crucitti T (2012) Vaginal microbiota assessment by real time PCR in the Mabgel1 study and the IPM013 Dapivirine ring trial. Microbicides Conference, Sydney, Australia Oral Abstract: 508."},{"key":"ref35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1128\/mBio.00370-12","article-title":"Twice-daily application of HIV microbicides alter the vaginal microbiota","volume":"3","author":"J Ravel","year":"2012","journal-title":"MBio"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S1473-3099(05)70298-X","article-title":"Intravaginal practices, bacterial vaginosis, and women&apos;s susceptibility to HIV infection: epidemiological evidence and biological mechanisms","volume":"5","author":"L Myer","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/OLQ.0b013e3181a4f695","article-title":"Disentangling contributions of reproductive tract infections to HIV acquisition in African Women","volume":"36","author":"JH van de Wijgert","year":"2009","journal-title":"Sex Transm Dis"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/sextrans-2011-050319","article-title":"Intermediate vaginal flora is associated with HIV prevalence as strongly as bacterial vaginosis in a cross-sectional study of participants screened for a randomised controlled trial","volume":"88","author":"FA Gu\u00e9dou","year":"2012","journal-title":"Sex Transm Infect"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/01.olq.0000431070.38601.03","article-title":"The evolving design and methods for trials evaluating the safety of candidate vaginal microbicides: a systematic review","volume":"40","author":"V Jespers","year":"2013","journal-title":"Sex Transm Dis"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"D Moher","year":"2001","journal-title":"JAMA"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"e1000251","DOI":"10.1371\/journal.pmed.1000251","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"7","author":"KF Schulz","year":"2010","journal-title":"PLoS Med"},{"issue":"9","key":"ref42","doi-asserted-by":"crossref","first-page":"e25165.","DOI":"10.1371\/journal.pone.0025165","article-title":"Phase 1 randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally","volume":"6","author":"DJ Lewis","year":"2011","journal-title":"PLoS One"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1097\/QAD.0b013e328314b5df","article-title":"Antigenic mimicry of the HIV envelope by AIDS-associated pathogens","volume":"22","author":"DC Dunlop","year":"2008","journal-title":"AIDS"},{"key":"ref44","unstructured":"CONRAD\/WHO (2004) Manual for the Standardization of Colposcopy for the Evaluation of Vaginal Products-Update. Geneva: World Health Organization, Department of Reproductive Health and Research. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.conrad.org\/publications\" xlink:type=\"simple\">http:\/\/www.conrad.org\/publications<\/ext-link>. Accessed 2013 May 1."},{"key":"ref45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1128\/JCM.29.2.297-301.1991","article-title":"Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation","volume":"29","author":"R Nugent","year":"1991","journal-title":"J Clin Microbiol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1574-695X.2002.tb00634.x","article-title":"Detection of bacterial vaginosis-related organisms by real-time PCR for Lactobacilli, Gardnerella vaginalis and Mycoplasma hominis","volume":"34","author":"MR Zariffard","year":"2002","journal-title":"FEMS Immunol Med Microbiol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1128\/JCM.42.7.3128-3136.2004","article-title":"Quantitative analysis of diverse Lactobacillus species present in advanced dental caries","volume":"42","author":"R Byun","year":"2004","journal-title":"J Clin Microbiol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-2334-7-128","article-title":"Association between Lactobacillus species and bacterial vaginosis-related bacteria, and bacterial vaginosis scores in pregnant Japanese women","volume":"7","author":"R Tamrakar","year":"2007","journal-title":"BMC Infect Dis"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1471-2180-7-115","article-title":"Quantitative determination by realtime PCR of four vaginal Lactobacillus species, Gardnerella vaginalis and Atopobium vaginae indicates an inverse relationship between L. gasseri and L. iners","volume":"7","author":"E De Backer","year":"2007","journal-title":"BMC Microbiol"},{"key":"ref50","unstructured":"Microbicides Development Programme (MDP) (2007) Trial Protocol for MDP 301: An international multi-centre, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of 0.5% and 2% PRO 2000\/5 gels for the prevention of vaginally acquired HIV infection, version 1.4. London: Microbicides Development Programme, Medical Research Council. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.mdp.mrc.ac.uk\/publications_documents\/MDP301_1.4_291107.pdf\" xlink:type=\"simple\">http:\/\/www.mdp.mrc.ac.uk\/publications_documents\/MDP301_1.4_291107.pdf<\/ext-link>. Accessed 2012 September 22."},{"key":"ref51","unstructured":"United States National Institutes of Health Division of AIDS (2004) Table for grading the severity of adult and pediatric adverse events, version 1.0. Bethesda, MA: United States National Institutes of Health Division of AIDS, United States Department for Health and Human Services. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ucdmc.ucdavis.edu\/clinicaltrials\/documents\/DAIDS_AE_GradingTable_FinalDec2004.pdf\" xlink:type=\"simple\">http:\/\/www.ucdmc.ucdavis.edu\/clinicaltrials\/documents\/DAIDS_AE_GradingTable_FinalDec2004.pdf<\/ext-link>. Accessed 2012 September 22."},{"key":"ref52","article-title":"Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol","author":"C Moog","year":"2013","journal-title":"Epub ahead of print"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1126\/science.1083182","article-title":"Antibody domain exchange is an immunological solution to carbohydrate cluster recognition","volume":"300","author":"DA Calarese","year":"2003","journal-title":"Science"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1002\/jps.21180","article-title":"Heterogeneity of monoclonal antibodies","volume":"97","author":"H Liu","year":"2008","journal-title":"J Pharm Sci"},{"key":"ref55","first-page":"180","article-title":"The vaginal microflora of pig-tailed macaques and the effects of chlorhexidine and benzalkonium on this ecosystem. Sex Transm Dis 23: 489\u2013493","volume":"24","author":"DL Patton","year":"1996","journal-title":"Erratum (1997) in: Sex Transm Dis"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1600-0684.2004.00059.x","article-title":"Macaca fascicularis vs. Macaca nemestrina as a model for topical microbicide safety studies","volume":"33","author":"DL Patton","year":"2004","journal-title":"J Med Primatol"},{"key":"ref57","first-page":"39","article-title":"Comparison of pH measurement devices for determining vaginal pH in cynomolgus macaques","volume":"43","author":"GE De Los Santos","year":"2004","journal-title":"Contemp Top Lab Anim Sci"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1128\/JCM.27.6.1266-1271.1989","article-title":"Comparison of methods for diagnosing bacterial vaginosis among pregnant women","volume":"27","author":"MA Krohn","year":"1989","journal-title":"J Clin Microbiol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1124\/dmd.111.039453","article-title":"Monoclonal antibodies with identical Fc sequences can bind FcRN differentially with pharmacokinetic consequences","volume":"39","author":"W Wang","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"ref60","doi-asserted-by":"crossref","first-page":"e1003776","DOI":"10.1371\/journal.ppat.1003776","article-title":"The Neonatal Fc Receptor (FcRn) Enhances Human Immunodeficiency Virus Type 1 (HIV-1) Transcytosis across Epithelial Cells","volume":"9","author":"S Gupta","year":"2013","journal-title":"PLoS Pathog"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1021\/bc100261d","article-title":"Effects of charge on antibody tissue distribution and pharmacokinetics","volume":"21","author":"CA Boswell","year":"2010","journal-title":"Bioconjugate Chem"},{"key":"ref62","first-page":"15","article-title":"Transport of immunoglobulin G by endothelial vesicles in isolated capillaries","volume":"2","author":"JJ Devenny","year":"1985","journal-title":"Microcirc Endothelium Lymphatics"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/10611860008996853","article-title":"Enhanced cellular uptake and transport of polyclonal immunoglobulin G and fab after their cationization","volume":"8","author":"G Hong","year":"2000","journal-title":"J Drug Target"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"20234","DOI":"10.1073\/pnas.0908713106","article-title":"Role of HIV membrane in neutralization by two broadly neutralizing antibodies","volume":"106","author":"SM Alam","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1095\/biolreprod.110.090423","article-title":"Structure and function of intercellular junctions in human cervical and vaginal mucosal epithelia","volume":"85","author":"CD Blaskewicz","year":"2011","journal-title":"Biol Reprod"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"11181","DOI":"10.1073\/pnas.1103012108","article-title":"Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody","volume":"108","author":"DR Burton","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"6189","DOI":"10.1128\/JVI.00491-12","article-title":"A non-fucosylated variant of the the anti-HIV-1 MAb b12 has enhanced Fc\u03b3RIIIa-mediated antiviral activity in vitro but not improved protection against mucosal SHIV challenge in macaques","volume":"86","author":"B Moldt","year":"2012","journal-title":"J Virol"},{"key":"ref68","unstructured":"Klein K, Veazey RS, Warrier R, Hraber P, Doyle-Meyers LA, <etal>et al<\/etal>.<bold>.<\/bold> (2013) Features of neutralizing antibodies at the portal of infection associated with protection against vaginal SHIV challenge. J Virol in press."},{"key":"ref69","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"X Wu","year":"2010","journal-title":"Science"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature11544","article-title":"Broad and potent neutralization of HIV-1 by a gp41-specific human antibody","volume":"491","author":"J Huang","year":"2012","journal-title":"Nature"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1084\/jem.20101907","article-title":"MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1","volume":"208","author":"CR Ruprecht","year":"2011","journal-title":"J Exp Med"},{"key":"ref72","unstructured":"Scott Y, Whaley K, Dezzutti C (2013) Higher Quantities of Broadly Neutralizing Monoclonal Antibodies Are Required to Protect Human Mucosal Tissue from HIV-1 Infection. Abstract #989. 20<sup>th<\/sup> Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, USA; March 3\u20136, 2013."},{"key":"ref73","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/sti.2009.038372","article-title":"A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda","volume":"86","author":"A Kamali","year":"2010","journal-title":"Sex Transm Inf"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/bab.6","article-title":"Plant-made pharmaceuticals: Leading products and production platforms","volume":"58","author":"M Paul","year":"2011","journal-title":"Biotechnol Appl Biochem"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.biotechadv.2011.08.020","article-title":"Green factory: Plants as bioproduction platforms for recombinant proteins","volume":"30","author":"J Xu","year":"2012","journal-title":"Biotechnol Adv"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nature10660","article-title":"Antibody-based protection against HIV infection by vectored immunoprophylaxis","volume":"481","author":"AB Balazs","year":"2011","journal-title":"Nature"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"e26473","DOI":"10.1371\/journal.pone.0026473","article-title":"Anti-gp120 minibody gene transfer to female genital epithelial cells protects against HIV-1 virus challenge <italic>in vitro<\/italic>","volume":"6","author":"UM Abdel-Motal","year":"2011","journal-title":"PLoS ONE"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nm.3471","article-title":"Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission","volume":"20","author":"AB Balazs","year":"2014","journal-title":"Nat Med"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0116153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T12:48:57Z","timestamp":1598618937000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0116153"}},"subtitle":[],"editor":[{"given":"Gilda","family":"Tachedjian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,12,29]]},"references-count":78,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,12,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0116153","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,29]]}}}